Lupin dips 3% as US FDA issues warning letter for Tarapur facility

Lupin said it does not believe the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

Lupin
Premium

Lupin

SI Reporter Mumbai
Shares of Lupin dipped 3 per cent to Rs 652 on the BSE in Thursday's intra-day trade after the company received warning letter for its Tarapur, Maharashtra facility. During the past four trading days, the stock gained 3.4 per cent in an otherwise weak market.

Lupin, in an exchange filing today, said it has received a warning letter from the United States Food and Drug Administration (USFDA) for the company’s Tarapur, Maharashtra, facility after they inspected site from March 22, 2022 to April 4, 2022.

The company said it does not believe that the warning letter will have

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 29 2022 | 10:59 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com